Most notably, the Factor IX Padua variant60, a naturally occurring Factor IX variant with increased activity has been shown to improve the efficacy of hemophilia B gene therapy by up to 10-fold in preclinical studies61 and has shown promising results in clinical trials62. Here, F9 is linked to hemophilia B.